Delivered-To: tjphuhs@gmail.com Received: by 2002:a5d:5410:0:b0:43d:6172:49f8 with SMTP id g16csp627392wrv; Fri, 10 Apr 2026 11:27:06 -0700 (PDT) X-Received: by 2002:a05:622a:4d3:b0:509:1e86:fce8 with SMTP id d75a77b69052e-50dd5c3820bmr64324611cf.64.1775845625773; Fri, 10 Apr 2026 11:27:05 -0700 (PDT) ARC-Seal: i=1; a=rsa-sha256; t=1775845625; cv=none; d=google.com; s=arc-20240605; b=SE4QT47G1p80zlVLtfwUxikAkf+bJBtqtZnnxlFUH7Sn1IVzWXLwXEB1B/+C+BbPZ9 juxyaPz+rmhnBCu0Ey1LBS2EIvVAVpbRZ8RlyQw++vy/YhfZWL1rbKOXiXGBaNeB5BeH lXwEnLvkCJ7wKExT3HajbuxyjMUga1FkKPp5goLZLwgs7R/IQh+fC/WUfe11n2Dl7mIC 4/8Bfjm/N/oul0oWu/Xr7YUi81ajIoFWdb/85DWGggCAgm2xyfL0/YKKdm6FrfttgDoa LLGRYpUngifto3NnV/TdZpvOBYK8iHp1k7mIZsRzPSO/Q5B0ym19+8Nu3qWRBfn+bmG7 iqrw== ARC-Message-Signature: i=1; a=rsa-sha256; c=relaxed/relaxed; d=google.com; s=arc-20240605; h=list-unsubscribe-post:list-unsubscribe:list-post:list-id :list-archive:list-url:list-owner:reply-to:in-reply-to:references :sender:feedback-id:date:message-id:to:from:subject:mime-version :dkim-signature:dkim-signature; bh=mjnBGCdDDFbM3xRCZYFPqZUzD4G2ojSlAH9OAz+r2Rs=; fh=9zP21OW67FFZD2VV42mGudo540Qp4aalMWxJB5kMYug=; b=YT02GAlploz2KWN9w3c2v10KPwL3xWO8XXTweQU1PbG68mAN+3MbVZOfcNmxrnwcwe RVLcwkegUJV5NBKmMUmqTmwM2VpXfuGeTnFaf38xL0dpWMgmMgxe46So3W87ZZTdjh2t 6pe8VehoHYMgzFUeNuMIpmgJ2m7e5QyGV8YZD7EaJbLz97/AekIRlYc3zD0wbys7eDVo hv4qj8L5QgzbbX2DDcUubkMCo3F4ZNSYKvtJsC2j9GhCarrfHbJZ0qrk2uuaWgRRqs1N BRUWVGSzqUDlqVHLmiU+KCJjzMoMUdWVcOIIGYXVmkz7gZ7zr7gxxK0IU2b74Klfz+rd Z7oQ==; dara=google.com ARC-Authentication-Results: i=1; mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=aLkLUQM7; dkim=pass header.i=@mailgun.org header.s=mg header.b=c1G58OHy; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.44 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com Return-Path: Received: from v544.v5375b7fa.use4.send.mailgun.net (v544.v5375b7fa.use4.send.mailgun.net. [159.112.244.44]) by mx.google.com with UTF8SMTPS id d75a77b69052e-50dd564c55dsi39702441cf.121.2026.04.10.11.27.05 for (version=TLS1_2 cipher=ECDHE-ECDSA-AES128-GCM-SHA256 bits=128/128); Fri, 10 Apr 2026 11:27:05 -0700 (PDT) Received-SPF: pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.44 as permitted sender) client-ip=159.112.244.44; Authentication-Results: mx.google.com; dkim=pass header.i=@mg-d0.substack.com header.s=mailo header.b=aLkLUQM7; dkim=pass header.i=@mailgun.org header.s=mg header.b=c1G58OHy; spf=pass (google.com: domain of bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com designates 159.112.244.44 as permitted sender) smtp.mailfrom="bounce+91e48a.63af5d-tjphuhs=gmail.com@mg-d0.substack.com"; dmarc=pass (p=REJECT sp=REJECT dis=NONE) header.from=substack.com DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mg-d0.substack.com; q=dns/txt; s=mailo; t=1775845625; x=1775852825; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=mjnBGCdDDFbM3xRCZYFPqZUzD4G2ojSlAH9OAz+r2Rs=; b=aLkLUQM7/RBHxgc54H4tvn+bn2p7tUIfXEF/+EXtDGN9YiRHQDGQ+fbPpzUjSeHIydeGlMuDfKb/LkgXtzu9soOo91mi9ySzyfnMmrVprYpWUAp3CCW3ja95m7nPkWVdpqRIA3jMFB26e33qPZQEH0ASruKwe/HbZNqZkI1xAXs= DKIM-Signature: a=rsa-sha256; v=1; c=relaxed/relaxed; d=mailgun.org; q=dns/txt; s=mg; t=1775845625; x=1775852825; h=List-Unsubscribe-Post: List-Unsubscribe: List-Post: List-Id: List-Archive: List-Owner: Reply-To: In-Reply-To: References: Sender: Sender: Date: Message-Id: To: To: From: From: Subject: Subject: Content-Type: Mime-Version: X-Feedback-Id; bh=mjnBGCdDDFbM3xRCZYFPqZUzD4G2ojSlAH9OAz+r2Rs=; b=c1G58OHyRwRoFG34egHTpzYZyAFBzBiatXLbIDQNGJuam2vnikV/fJQN9ViTfkxOM8lSTx11DjLrCqq771fPBwWvB2lsKDszXx50QsVbgB4H18aIXlWk811VzeC0ReDRXzHvsUeFnFSUtgoCGDzvSvCARBr5e4gS0F4cQ1vtydw= X-Mailgun-Sid: WyJkZWU4NyIsInRqcGh1aHNAZ21haWwuY29tIiwiNjNhZjVkIl0= X-Feedback-Id: postmaster@mg-d0.substack.com:post:6148c7d8a45790427cda307f:mailgun Received: by 825a688eb61e582a40560155fe766abbf33a683f676475d94145671c1ab0b587 with HTTP id 69d940f83cfe59f61df0e740; Fri, 10 Apr 2026 18:27:04 GMT X-Mailgun-Sending-Ip: 159.112.244.44 Mime-Version: 1.0 Content-Type: multipart/alternative; boundary="1709fd6c8d9de68609bbb0d7e360f78ac8c05ff8b65c0c829147425da51b" Subject: GHK-Cu: What Happens at the Cellular Level When a Protocol Ends? From: Derek from Research Radar To: tjphuhs@gmail.com X-Mailgun-Tag: post X-Mailgun-Track-Clicks: false Message-Id: <20260410182657.3.3ccc94e39cf07279@mg-d0.substack.com> Date: Fri, 10 Apr 2026 18:26:57 +0000 Feedback-Id: post-193822129:cat-post:pub-3365367:substack Sender: Derek from Research Radar References: In-Reply-To: Reply-To: Derek from Research Radar List-Owner: List-Url: List-Archive: List-Id: List-Post: List-Unsubscribe: List-Unsubscribe-Post: List-Unsubscribe=One-Click X-Mailgun-Variables: {"category": "post", "email_generated_at": "1775845624899", "is_freemail": "true", "post_audience": "everyone", "post_id": "193822129", "post_type": "newsletter", "pub_community_enabled": "true", "publication_id": "3365367", "subdomain": "derekpruski", "user_id": "273622398"} --1709fd6c8d9de68609bbb0d7e360f78ac8c05ff8b65c0c829147425da51b Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: quoted-printable View this post on the web at https://derekpruski.substack.com/p/ghk-cu-what= -happens-at-the-cellular For research use only. Not for human consumption. What is GHK-Cu? GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is a naturally occurring copper = peptide first isolated from plasma in 1973. It is found naturally in the bo= dy and has been studied extensively in research settings. Rather than acting as a filler or surface compound, GHK-Cu functions as a b= iological signaling molecule. Research has documented it activating the cel= lular machinery responsible for building and remodeling connective tissue, = including stimulating collagen and elastin synthesis, reducing inflammation= markers, and influencing gene expression across thousands of pathways asso= ciated with tissue aging. Topical vs Sub-Q: Why administration format matters Topical application delivers GHK-Cu to the upper dermal layers with localiz= ed fibroblast activation and collagen upregulation in the application area.= Penetration is naturally limited by the skin barrier. Sub-Q administration bypasses the skin barrier entirely, entering systemic = circulation more readily. Research documents faster onset of measurable bio= logical activity and broader distribution of effect with sub-Q models, cons= istent with higher bioavailability through this route. Simply put: sub-Q reaches more tissue, faster, and builds a larger foundati= on of structural remodeling going into the post-protocol window. Observed onset timelines during active research protocols Topical models: Weeks 2 to 4: Measurable increases in fibroblast activity and early collage= n synthesis markers Weeks 4 to 8: Documented upregulation of collagen I and III gene expression= , elastin synthesis begins Months 3 to 6: Cumulative collagen deposition and structural remodeling mos= t apparent in tissue analysis Sub-Q models: Weeks 1 to 2: Earlier measurable increases in collagen synthesis markers du= e to higher bioavailability Weeks 3 to 6: More pronounced fibroblast activation and extracellular matri= x remodeling compared to topical Months 2 to 4: Deeper structural remodeling documented at the tissue level What happens week by week after discontinuation? This is the part most researchers want to understand clearly. The important foundation to know first: collagen, once synthesized, has a b= iological half-life measured in months to years. Type I collagen specifical= ly has a documented half-life of over a year under stable tissue conditions= =2E So the collagen produced during an=20= active protocol does not rapidly break= down the moment administration stops. What does change immediately is the upstream signaling. Without continued G= HK-Cu, the gene expression activity driving collagen synthesis begins retur= ning toward baseline. Here is how that plays out week by week: Weeks 1 to 2 post-discontinuation The cellular signaling driven by GHK-Cu b= egins declining, but collagen and structural proteins already deposited rem= ain largely intact. Research markers for active synthesis start pulling bac= k but have not yet shown meaningful regression. This window looks very simi= lar to the tail end of an active protocol. Weeks 2 to 4 post-discontinuation Fibroblast activation begins normalizing = toward baseline. Active collagen synthesis rates measurably decline during = this window. However, the structural proteins already built continue to exi= st given their biological half-life. The gap between peak synthesis activit= y and current activity widens, but deposited collagen is not yet meaningful= ly degrading. Weeks 4 to 8 post-discontinuation This is the window where research documen= ts the most meaningful regression in active remodeling markers. The upstrea= m signaling has largely normalized toward pre-protocol baseline by this poi= nt. Existing collagen continues its natural biological turnover, but the re= placement rate has dropped significantly without the GHK-Cu stimulus drivin= g synthesis. This is when the difference between peak protocol activity and= post-discontinuation state becomes most measurable. Beyond 8 weeks post-discontinuation Without reintroduction of the signaling= stimulus, collagen synthesis rates settle at age-appropriate baseline leve= ls. Previously deposited collagen continues normal biological turnover with= out being replaced at the elevated rate seen during the active protocol. Ov= er months to a year or more, the cumulative structural remodeling achieved = during the protocol gradually diminishes as natural degradation outpaces ba= seline synthesis. Sub-Q protocols show a similar post-discontinuation pattern, though the lar= ger baseline of structural remodeling achieved during the active phase mean= s the absolute level of collagen present remains higher for longer compared= to topical models. Does everything return to pre-protocol baseline? Not immediately, and research suggests not fully in the short term. GHK-Cu= =E2=80=99s influence on gene expression includes epigenetic markers that ma= y persist beyond active administration. Whether these changes are durable l= ong term remains an active area of research interest. What the literature consistently supports is that maintenance dosing sustai= ns elevated collagen synthesis activity more effectively than repeated cold= -start protocols, given the cumulative nature of structural remodeling. Bottom line GHK-Cu drives collagen synthesis through well-documented signaling mechanis= ms. The structural proteins built during a protocol have biological staying= power well beyond discontinuation due to collagen=E2=80=99s natural half-l= ife. However, the cellular signal driving continued production begins fadin= g within the first few weeks of stopping, with the most meaningful regressi= on in active synthesis markers occurring in the 4 to 8 week post-discontinu= ation window. Peak activity will not be maintained without continued admini= stration, and maintenance dosing is better supported in the literature than= cycling repeatedly from baseline. Unsubscribe https://substack.com/redirect/2/eyJlIjoiaHR0cHM6Ly9kZXJla3BydXN= raS5zdWJzdGFjay5jb20vYWN0aW9uL2Rpc2FibGVfZW1haWw_dG9rZW49ZXlKMWMyVnlYMmxrSW= pveU56TTJNakl6T1Rnc0luQnZjM1JmYVdRaU9qRTVNemd5TWpFeU9Td2lhV0YwSWpveE56YzFPR= FExTmpJMExDSmxlSEFpT2pFNE1EY3pPREUyTWpRc0ltbHpjeUk2SW5CMVlpMHpNelkxTXpZM0lp= d2ljM1ZpSWpvaVpHbHpZV0pzWlY5bGJXRnBiQ0o5Lk1RNmwxd1llRWJLWW5kOFlJNXpNQlVnNjN= 3OEdRb2FBN1cwTDhKaTNGcUUiLCJwIjoxOTM4MjIxMjksInMiOjMzNjUzNjcsImYiOnRydWUsIn= UiOjI3MzYyMjM5OCwiaWF0IjoxNzc1ODQ1NjI0LCJleHAiOjIwOTE0MjE2MjQsImlzcyI6InB1Y= i0wIiwic3ViIjoibGluay1yZWRpcmVjdCJ9.Ww24dTFohaiYKMnFEdtZ6lw9w9nsimsadz9sT_X= Xn7w? --1709fd6c8d9de68609bbb0d7e360f78ac8c05ff8b65c0c829147425da51b Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable = GHK-Cu: What Happens at the Cellular Level When a Protocol Ends? @media (max-width: 1024px) { .typography .pullquote-align-left, .typography.editor .pullquote-align-left, .typography .pullquote-align-right, .typography.editor .pullquote-align-right, .typography .pullquote-align-wide, .typography.editor .pullquote-align-wide, .typography .pullquote-align-center, .typography.editor .pullquote-align-center { float: none; margin: 0 auto; width: 100%; max-width: 100%; } } @media all and (-ms-high-contrast: none), (-ms-high-contrast: active) { .typography .markup table.image-wrapper img, .typography.editor .markup table.image-wrapper img, .typography .markup table.kindle-wrapper img, .typography.editor .markup table.kindle-wrapper img { max-width: 550px; } } @media (min-width: 1024px) { .typography:not(:has(#toc)) .captioned-image-container figure:has(> a.ima= ge2-offset-left), .typography.editor:not(:has(#toc)) .captioned-image-container figure:has(= > a.image2-offset-left) { margin-left: var(--image-offset-margin); } .typography:not(:has(#toc)) .captioned-image-container figure:has(> a.ima= ge2-offset-right), .typography.editor:not(:has(#toc)) .captioned-image-container figure:has(= > a.image2-offset-right) { margin-right: var(--image-offset-margin); } } @media (min-width: 1300px) { .typography .captioned-image-container figure:has(> a.image2-offset-left)= , .typography.editor .captioned-image-container figure:has(> a.image2-offse= t-left) { margin-left: var(--image-offset-margin); } .typography .captioned-image-container figure:has(> a.image2-offset-right= ), .typography.editor .captioned-image-container figure:has(> a.image2-offse= t-right) { margin-right: var(--image-offset-margin); } } @media (max-width: 1024px) { .typography, .typography.editor { /* Disable offset on mobile/tablet */ } .typography .captioned-image-container figure:has(> a.image2-align-left), .typography.editor .captioned-image-container figure:has(> a.image2-align= -left), .typography .captioned-image-container figure:has(> a.image2-align-right)= , .typography.editor .captioned-image-container figure:has(> a.image2-align= -right) { float: none; margin: 1em auto; max-width: 100%; width: auto; padding: 0; } .typography .captioned-image-container figure:has(> a.image2-align-left.t= hefp), .typography.editor .captioned-image-container figure:has(> a.image2-align= -left.thefp), .typography .captioned-image-container figure:has(> a.image2-align-right.= thefp), .typography.editor .captioned-image-container figure:has(> a.image2-align= -right.thefp) { margin: 1em auto; } .typography .captioned-image-container figure:has(> a.image2-offset-left)= , .typography.editor .captioned-image-container figure:has(> a.image2-offse= t-left), .typography .captioned-image-container figure:has(> a.image2-offset-right= ), .typography.editor .captioned-image-container figure:has(> a.image2-offse= t-right) { margin: 1em auto; } .typography .captioned-image-container figure:has(> a.image2-align-left) = =2Eimage2-inset, .typography.editor .captioned-image-container figure:has(> a.image2-align= -left) .image2-inset, .typography .captioned-image-container figure:has(> a.image2-align-right)= .image2-inset, .typography.editor .captioned-image-container figure:has(> a.image2-align= -right) .image2-inset { display: block; justify-content: initial; } } @media (max-width: 768px) { .typography .markup div.sponsorship-campaign-embed, .typography.editor .markup div.sponsorship-campaign-embed { margin-top: 24px; margin-bottom: 24px; } .typography .markup div.sponsorship-campaign-embed:first-child, .typography.editor .markup div.sponsorship-campaign-embed:first-child { margin-top: 0px; } } @media screen and (max-width: 650px) { .typography .markup div.youtube-overlay, .typography.editor .markup div.youtube-overlay, .typography .markup div.vimeo-overlay, .typography.editor .markup div.vimeo-overlay { display: none !important; } } @media screen and (max-width: 370px) { .typography .markup div.tiktok-wrap, .typography.editor .markup div.tiktok-wrap { width: calc(95vw - 32px); height: calc((95vw - 32px - 2px) / 0.485714); } } @media screen and (max-width: 650px) { .typography .markup div.embedded-publication-wrap .embedded-publication.s= how-subscribe, .typography.editor .markup div.embedded-publication-wrap .embedded-public= ation.show-subscribe { padding: 24px; } } @media screen and (max-width: 650px) { .typography .markup div.subscription-widget-wrap .subscription-widget.sho= w-subscribe, .typography.editor .markup div.subscription-widget-wrap .subscription-wid= get.show-subscribe, .typography .markup div.subscription-widget-wrap-editor .subscription-wid= get.show-subscribe, .typography.editor .markup div.subscription-widget-wrap-editor .subscript= ion-widget.show-subscribe, .typography .markup div.captioned-button-wrap .subscription-widget.show-s= ubscribe, .typography.editor .markup div.captioned-button-wrap .subscription-widget= =2Eshow-subscribe { padding: 0px 24px; } } @media screen and (max-width: 650px) { .typography .markup div.subscription-widget-wrap .subscription-widget.sho= w-subscribe .subscription-widget-subscribe .button, .typography.editor .markup div.subscription-widget-wrap .subscription-wid= get.show-subscribe .subscription-widget-subscribe .button, .typography .markup div.subscription-widget-wrap-editor .subscription-wid= get.show-subscribe .subscription-widget-subscribe .button, .typography.editor .markup div.subscription-widget-wrap-editor .subscript= ion-widget.show-subscribe .subscription-widget-subscribe .button, .typography .markup div.captioned-button-wrap .subscription-widget.show-s= ubscribe .subscription-widget-subscribe .button, .typography.editor .markup div.captioned-button-wrap .subscription-widget= =2Eshow-subscribe .subscription-widget-subscribe .button { padding: 10px 12px; min-width: 110px; } } @media (max-width: 650px) { .typography .markup .twitter-embed, .typography.editor .markup .twitter-embed, .typography .markup .tweet, .typography.editor .markup .tweet { padding: 12px; } } @media (max-width: 650px) { .typography .markup .twitter-embed .tweet-text, .typography.editor .markup .twitter-embed .tweet-text, .typography .markup .tweet .tweet-text, .typography.editor .markup .tweet .tweet-text { font-size: 14px; line-height: 20px; } } @media (max-width: 650px) { .typography .markup .twitter-embed .tweet-photos-container.two, .typography.editor .markup .twitter-embed .tweet-photos-container.two, .typography .markup .tweet .tweet-photos-container.two, .typography.editor .markup .tweet .tweet-photos-container.two, .typography .markup .twitter-embed .tweet-photos-container.three, .typography.editor .markup .twitter-embed .tweet-photos-container.three, .typography .markup .tweet .tweet-photos-container.three, .typography.editor .markup .tweet .tweet-photos-container.three, .typography .markup .twitter-embed .tweet-photos-container.four, .typography.editor .markup .twitter-embed .tweet-photos-container.four, .typography .markup .tweet .tweet-photos-container.four, .typography.editor .markup .tweet .tweet-photos-container.four { height: 200px; } } @media (max-width: 650px) { .typography .markup .twitter-embed a.expanded-link .expanded-link-img, .typography.editor .markup .twitter-embed a.expanded-link .expanded-link-= img, .typography .markup .tweet a.expanded-link .expanded-link-img, .typography.editor .markup .tweet a.expanded-link .expanded-link-img { max-height: 180px; } } @media (max-width: 650px) { .typography .markup .twitter-embed a.expanded-link .expanded-link-descrip= tion, .typography.editor .markup .twitter-embed a.expanded-link .expanded-link-= description, .typography .markup .tweet a.expanded-link .expanded-link-description, .typography.editor .markup .tweet a.expanded-link .expanded-link-descript= ion { display: none; } } @media screen and (max-width: 650px) { .typography .markup .apple-podcast-container, .typography.editor .markup .apple-podcast-container { width: unset; } } @media (max-width: 420px) { .typography .markup .install-substack-app-embed img.install-substack-app-= embed-img, .typography.editor .markup .install-substack-app-embed img.install-substa= ck-app-embed-img { margin: 0 auto 16px auto; } } @media (max-width: 420px) { .typography .markup .install-substack-app-embed .install-substack-app-emb= ed-text, .typography.editor .markup .install-substack-app-embed .install-substack-= app-embed-text { margin: 0 0 12px 0; max-width: 100%; width: auto; text-align: center; } } @media (max-width: 420px) { .typography .markup .install-substack-app-embed .install-substack-app-emb= ed-link, .typography.editor .markup .install-substack-app-embed .install-substack-= app-embed-link { display: flex; justify-content: center; } } @media screen and (min-width: 481px) { .share-button-container { height: 38px; } } @media screen and (min-width: 481px) { .share-button-container a.comment { height: 38px; line-height: 38px; padding-right: 10px; } } @media screen and (max-width: 480px) { .share-button-container .separator { display: block; margin: 0; height: 8px; border-left: none; } } @media screen and (max-width: 480px) { .share-button-container a.share.first img { padding-left: 0; } } @media screen and (min-width: 481px) { .share-button-container a.mobile { display: none !important; } } @media screen and (min-width: 541px) { .settings-add-pub-modal-wrapper .container .add-recommending-pub-modal-co= ntainer { padding: 36px; height: 680px; } } @media screen and (min-width: 541px) { .settings-add-pub-modal-wrapper .container .add-recommending-pub-modal-co= ntainer .footer { position: absolute; bottom: 36px; margin: 0px; } } @media screen and (max-width: 650px) { .header-anchor-parent { display: none; } } @media screen and (max-width: 768px) { .post { padding: 16px 0 0 0; } } @media screen and (max-width: 650px) { .post .post-header .post-label { margin-top: 8px; } } @media screen and (max-width: 650px) { .post .post-header .meta-author-wrap.alternative-meta .meta-right-column = =2Epost-meta { margin-top: 6px; } } @media screen and (max-width: 650px) { .post .footer-facepile-container { height: 64px; padding: 0 16px; display: flex; align-items: center; justify-content: flex-start; width: 100%; } } @media screen and (max-width: 650px) { .post .post-footer.use-separators { justify-content: center; } } @media screen and (max-width: 650px) { .post .post-footer.next-prev { height: 64px; justify-content: space-between; box-sizing: border-box; } } @media screen and (max-width: 650px) { .post-contributor-footer .post-contributor-bio-table { display: block; } .post-contributor-footer .post-contributor-bio-table-row { display: flex; flex-direction: row; } .post-contributor-footer .post-contributor-bio-userhead-cell, .post-contributor-footer .post-contributor-bio-body-cell { display: block; } .post-contributor-footer .post-contributor-bio-body-cell { flex-grow: 1; } .post-contributor-footer .post-contributor-bio-body-table { display: block; } .post-contributor-footer .post-contributor-bio-body-table-row { display: block; } .post-contributor-footer .post-contributor-bio-copy-cell, .post-contributor-footer .post-contributor-bio-controls-cell { display: block; } .post-contributor-footer .post-contributor-bio-copy-cell { margin: 0 0 16px 0; } .post-contributor-footer .post-contributor-bio-controls-cell { width: auto; } .post-contributor-footer .post-contributor-bio-controls { margin: auto; } .post-contributor-footer .post-contributor-bio-controls .button.primary { width: 100%; } .post-contributor-footer .post-contributor-bio-text { font-size: 14px; } } @media screen and (min-width: 768px) { .post-silhouette { padding: 32px 0; } } @media screen and (max-width: 650px) { .post-silhouette .post-silhouette-title { margin-top: 10.44225025px; height: 120px; } } @media screen and (max-width: 650px) { .post-silhouette .post-silhouette-meta { width: 75%; } } @media screen and (max-width: 650px) { .post-silhouette .post-silhouette-meta.with-byline-image { margin: 20px 0; } } @media screen and (max-width: 650px) { .use-theme-bg .post-meta.alternative-meta .post-meta-item, .post-meta.alternative-meta .post-meta-item { padding-right: 16px; } } @media screen and (max-width: 370px) { .use-theme-bg .post-meta.alternative-meta .post-meta-item, .post-meta.alternative-meta .post-meta-item { font-size: 14px; } } @media screen and (max-width: 650px) { .use-theme-bg .post-meta.alternative-meta .post-meta-item.guest-author-pu= blication, .post-meta.alternative-meta .post-meta-item.guest-author-publication { display: none; } } @media screen and (max-width: 370px) { .post-meta .post-meta-item .post-meta-button { height: 36px !important; /* important to override in-line height style on emails */ } .post-meta .post-meta-item .post-meta-button .meta-button-label { display: none; } .post-meta .post-meta-item .post-meta-button > svg { margin-right: 0; } } @media screen and (max-width: 370px) { .post-meta .post-meta-item { font-size: 12px; } } @media screen and (max-width: 650px) { .post .floating-subscribe-button { bottom: 20px; right: 20px; } } @media (max-width: 1024px) { body .pullquote-align-left, body .pullquote-align-right, body .pullquote-align-wide, body .pullquote-align-center { float: none; margin: 0 auto; width: 100%; max-width: 100%; } } @media all and (-ms-high-contrast: none), (-ms-high-contrast: active) { body .markup table.image-wrapper img, body .markup table.kindle-wrapper img { max-width: 550px; } } @media (min-width: 1024px) { body:not(:has(#toc)) .captioned-image-container figure:has(> a.image2-off= set-left) { margin-left: var(--image-offset-margin); } body:not(:has(#toc)) .captioned-image-container figure:has(> a.image2-off= set-right) { margin-right: var(--image-offset-margin); } } @media (min-width: 1300px) { body .captioned-image-container figure:has(> a.image2-offset-left) { margin-left: var(--image-offset-margin); } body .captioned-image-container figure:has(> a.image2-offset-right) { margin-right: var(--image-offset-margin); } } @media (max-width: 1024px) { body { /* Disable offset on mobile/tablet */ } body .captioned-image-container figure:has(> a.image2-align-left), body .captioned-image-container figure:has(> a.image2-align-right) { float: none; margin: 1em auto; max-width: 100%; width: auto; padding: 0; } body .captioned-image-container figure:has(> a.image2-align-left.thefp), body .captioned-image-container figure:has(> a.image2-align-right.thefp) = { margin: 1em auto; } body .captioned-image-container figure:has(> a.image2-offset-left), body .captioned-image-container figure:has(> a.image2-offset-right) { margin: 1em auto; } body .captioned-image-container figure:has(> a.image2-align-left) .image2= -inset, body .captioned-image-container figure:has(> a.image2-align-right) .image= 2-inset { display: block; justify-content: initial; } } @media (max-width: 768px) { body .markup div.sponsorship-campaign-embed { margin-top: 24px; margin-bottom: 24px; } body .markup div.sponsorship-campaign-embed:first-child { margin-top: 0px; } } @media screen and (max-width: 650px) { body .markup div.youtube-overlay, body .markup div.vimeo-overlay { display: none !important; } } @media screen and (max-width: 370px) { body .markup div.tiktok-wrap { width: calc(95vw - 32px); height: calc((95vw - 32px - 2px) / 0.485714); } } @media screen and (max-width: 650px) { body .markup div.embedded-publication-wrap .embedded-publication.show-sub= scribe { padding: 24px; } } @media screen and (max-width: 650px) { body .markup div.subscription-widget-wrap .subscription-widget.show-subsc= ribe, body .markup div.subscription-widget-wrap-editor .subscription-widget.sho= w-subscribe, body .markup div.captioned-button-wrap .subscription-widget.show-subscrib= e { padding: 0px 24px; } } @media screen and (max-width: 650px) { body .markup div.subscription-widget-wrap .subscription-widget.show-subsc= ribe .subscription-widget-subscribe .button, body .markup div.subscription-widget-wrap-editor .subscription-widget.sho= w-subscribe .subscription-widget-subscribe .button, body .markup div.captioned-button-wrap .subscription-widget.show-subscrib= e .subscription-widget-subscribe .button { padding: 10px 12px; min-width: 110px; } } @media (max-width: 650px) { body .markup .twitter-embed, body .markup .tweet { padding: 12px; } } @media (max-width: 650px) { body .markup .twitter-embed .tweet-text, body .markup .tweet .tweet-text { font-size: 14px; line-height: 20px; } } @media (max-width: 650px) { body .markup .twitter-embed .tweet-photos-container.two, body .markup .tweet .tweet-photos-container.two, body .markup .twitter-embed .tweet-photos-container.three, body .markup .tweet .tweet-photos-container.three, body .markup .twitter-embed .tweet-photos-container.four, body .markup .tweet .tweet-photos-container.four { height: 200px; } } @media (max-width: 650px) { body .markup .twitter-embed a.expanded-link .expanded-link-img, body .markup .tweet a.expanded-link .expanded-link-img { max-height: 180px; } } @media (max-width: 650px) { body .markup .twitter-embed a.expanded-link .expanded-link-description, body .markup .tweet a.expanded-link .expanded-link-description { display: none; } } @media screen and (max-width: 650px) { body .markup .apple-podcast-container { width: unset; } } @media (max-width: 420px) { body .markup .install-substack-app-embed img.install-substack-app-embed-i= mg { margin: 0 auto 16px auto; } } @media (max-width: 420px) { body .markup .install-substack-app-embed .install-substack-app-embed-text= { margin: 0 0 12px 0; max-width: 100%; width: auto; text-align: center; } } @media (max-width: 420px) { body .markup .install-substack-app-embed .install-substack-app-embed-link= { display: flex; justify-content: center; } } @media screen and (min-width: 500px) { body .header a.logo { width: 42px; height: 42px; border-radius: 12px; } } @media screen and (max-width: 420px) { body .subscription-receipt table:first-of-type .subscription-amount .subs= cription-discount { width: 72px !important; } } @media screen and (min-width: 481px) { body .share-button-container { height: auto; } } @media screen and (max-width: 480px) { body .share-button-container .separator { display: block !important; margin: 0 !important; height: 8px !important; border-left: none !important; } } @media screen and (max-width: 650px) { .digest .item .post-meta-item.audience { display: none; } } @media screen and (min-width: 500px) { .digest-publication .logo img { width: 42px; height: 42px; border-radius: 8px; } } @media screen and (max-width: 650px) { .comments-page .container .comment-list .collapsed-reply { margin-left: calc(10 + 32px - 24px); } } @media screen and (max-width: 650px) { .comment > .comment-list { padding-left: 24px; } } @media screen and (max-width: 650px) { .finish-magic-login-modal .modal-content .container { padding: 24px 0; } } @media (max-width: 650px) { .reader2-text-b3 { line-height: 24px; } } @media screen and (max-width: 650px) { .reader2-text-h4 { line-height: 24px; } } @media screen and (min-width: 541px) { .user-profile-modal { padding-left: 12px; padding-right: 12px; } } @media screen and (max-width: 650px) { .subscribe-widget form.form .sideBySideWrap button.rightButton { padding: 10px 12px; } } @media screen and (min-width: 541px) { .pub-icon:hover .logo-hover, .feed-item-icon:hover .logo-hover { display: block; } } @media screen and (max-width: 650px) { .post-ufi.single-full-width-button .post-ufi-button-wrapper { width: 100%; padding: 16px; } .post-ufi.single-full-width-button .post-ufi-button-wrapper:empty { display: none; } .post-ufi.single-full-width-button .post-ufi-button { width: 100%; justify-content: center; } } @media screen and (max-width: 768px) { .file-embed-wrapper { padding: 0; } } @media screen and (max-width: 768px) { .file-embed-wrapper-editor { padding: 0; } } @media screen and (max-width: 768px) { .file-embed-wrapper-editor:active { padding: 0; } } @media only screen and (max-width: 650px) { .file-embed-button.wide, .file-embed-error-button.wide { display: none; } } @media only screen and (min-width: 630px) { .file-embed-button.narrow, .file-embed-error-button.narrow { display: none; } } @media screen and (min-width: 541px) { .audio-player-wrapper .audio-player { min-width: 500px; } } @media screen and (max-width: 650px) { .audio-player-wrapper .audio-player .audio-player-progress { border-left-width: 16px; border-right-width: 16px; } } @media screen and (max-width: 650px) { .audio-player-wrapper .audio-player .audio-player-progress .audio-player-= progress-bar .audio-player-progress-bar-popup { top: -54px; } } @media screen and (max-width: 650px) { .audio-player-wrapper-fancy .audio-player .audio-player-progress { border-left-width: 16px; border-right-width: 16px; } } @media screen and (max-width: 650px) { .audio-player-wrapper-fancy .audio-player .audio-player-progress .audio-p= layer-progress-bar .audio-player-progress-bar-popup { top: -54px; } } @media (min-width: 250px) { .audio-player-wrapper-fancy .audio-player { padding: 32px; } .audio-player-wrapper-fancy .audio-player .btn-group { display: flex; } .audio-player-wrapper-fancy .audio-player .btn-group .button:last-of-type= { display: block; } } @media (min-width: 300px) { .audio-player-wrapper-fancy .audio-player .btn-group { display: block; } .audio-player-wrapper-fancy .audio-player .btn-group .button:first-of-typ= e { display: block; } } @media (min-width: 350px) { .audio-player-wrapper-fancy .audio-player .audio-player-substack-logo { display: block; } .audio-player-wrapper-fancy .audio-player .audio-player-title { margin-top: 16px; } .audio-player-wrapper-fancy .audio-player .audio-player-hero-image-contai= ner { padding-top: 15%; width: 15%; display: block; } .audio-player-wrapper-fancy .audio-player .btn-group .button:first-of-typ= e { display: block; } .audio-player-wrapper-fancy .audio-player .audio-player-substack-logo { display: block; } } @media (min-width: 350px) { .audio-player-wrapper-fancy .audio-player .audio-player-hero-image-contai= ner { padding-top: 25%; width: 25%; display: block; } .audio-player-wrapper-fancy .audio-player .btn-group { display: flex; } .audio-player-wrapper-fancy .audio-player .btn-group .button:first-of-typ= e { display: block; } } @media (min-width: 400px) { .audio-player-wrapper-fancy .audio-player .audio-player-hero-image-contai= ner { padding-top: 40%; width: 40%; } } @media (max-width: 400px) { .audio-player-wrapper-fancy .audio-player .btn-group { margin-top: 12px; } .audio-player-wrapper-fancy .audio-player .btn-group .button { font-size: 13px; padding: 6px 12px; height: auto; margin-top: 10px; } } @media (min-width: 600px) { .audio-player-wrapper-fancy .audio-player .audio-player-hero-image-contai= ner { padding-top: 55%; width: 55%; } } @media (max-width: 650px) { .poll-editor-modal { min-width: calc(100% - 20px); } } @media (max-width: 750px) { .poll-embed .poll-anchor-target .poll-anchor-copy-button { left: 8px; top: 45px; } } @media not all and (min-resolution: 0.001dpcm) { @supports (-webkit-appearance: none) { p a:not(.primary.button), .post p:not(.button-wrapper) a:not(.primary.button), .footnote a.footnote-anchor:not(.primary.button), .thread-head .markup p:not(.button-wrapper) a:not(.primary.button) { color: #ff6719; text-decoration: none; } p a:not(.primary.button):hover, .post p:not(.button-wrapper) a:not(.primary.button):hover, .footnote a.footnote-anchor:not(.primary.button):hover, .thread-head .markup p:not(.button-wrapper) a:not(.primary.button):hove= r { text-decoration: underline; } } }=3D""
For research use only.
͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­͏     ­͏   ̳= 9; ­͏     ­͏     ­͏ &nb= sp;   ­͏     ­͏     ­&= #847;     ­͏     ­͏    = ; ­͏     ­͏     ­͏ &nbs= p;   ­͏     ­͏     ­&#= 847;     ­͏     ­͏    = ­͏     ­͏     ­͏  = ;   ­͏     ­͏     ­= 47;     ­͏     ­͏     = ­͏     ­͏     ­͏  =   ­͏     ­͏     ­T= 7;     ­͏     ­͏     &= #173;͏     ­͏     ­͏   =   ­͏     ­͏     ­͏= ;     ­͏     ­͏     &#= 173;͏     ­͏     ­͏   &= #8199; ­͏     ­͏     ­͏=     ­͏     ­͏     = 73;͏     ­͏     ­͏   &#= 8199; ­͏     ­͏     ­͏ =     ­͏     ­͏     = 3;͏     ­͏     ­͏   = 199; ­͏     ­͏     ­͏ &= nbsp;   ­͏     ­͏     ­= ;͏     ­͏     ­͏   Q= 99; ­͏     ­͏     ­͏ &n= bsp;   ­͏     ­͏     ­= ͏     ­
Forwar= ded this email? Subscribe here<= /a> for more

GHK-Cu: What Happens at the Cellular Level When a Pro= tocol Ends?

=
Derek
<= /tbody>
 
3D""
=
3D""
3D""
<= /td>
3D""
READ IN APP3D""
 

For research use only. Not = for human consumption.

What is GHK-Cu?

GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is a naturally occurr= ing copper peptide first isolated from plasma in 1973. It is found naturall= y in the body and has been studied extensively in research settings.

Rather than acting as a filler or surface compound, GHK-Cu functi= ons as a biological signaling molecule. Research has documented it activati= ng the cellular machinery responsible for building and remodeling connectiv= e tissue, including stimulating collagen and elastin synthesis, reducing in= flammation markers, and influencing gene expression across thousands of pat= hways associated with tissue aging.

=
3D""=

Topical vs Sub-Q: Why administration format mat= ters

Topical application delivers GHK-Cu to the up= per dermal layers with localized fibroblast activation and collagen upregul= ation in the application area. Penetration is naturally limited by the skin= barrier.

Sub-Q administration bypasses the skin barrier en= tirely, entering systemic circulation more readily. Research documents fast= er onset of measurable biological activity and broader distribution of effe= ct with sub-Q models, consistent with higher bioavailability through this r= oute.

Simply put: sub-Q reaches more tissue, faster, and bu= ilds a larger foundation of structural remodeling going into the post-proto= col window.

Observed onset timelines during active r= esearch protocols

Topical models:

  • Weeks 4 to 8: Documented upregulation of collagen I and III gene expre= ssion, elastin synthesis begins

  • Months 3 to 6: Cumulative collagen deposition and structural= remodeling most apparent in tissue analysis

Sub-= Q models:

  • Weeks 1 to 2: Earlier measurable increases in c= ollagen synthesis markers due to higher bioavailability

  • Weeks 3 to 6: More pronounced fibr= oblast activation and extracellular matrix remodeling compared to topical

  • Months 2 to 4: Dee= per structural remodeling documented at the tissue level

What happens week by week after discontinuation?

=

This is the part most researchers want to understand clearly.<= /p>

The important foundation to know first: collagen, once synt= hesized, has a biological half-life measured in months to years. Type I col= lagen specifically has a documented half-life of over a year under stable t= issue conditions. So the collagen produced during an active protocol does n= ot rapidly break down the moment administration stops.

What= does change immediately is the upstream signaling. Without continued GHK-C= u, the gene expression activity driving collagen synthesis begins returning= toward baseline. Here is how that plays out week by week:

= Weeks 1 to 2 post-discontinuation The cellular signa= ling driven by GHK-Cu begins declining, but collagen and structural protein= s already deposited remain largely intact. Research markers for active synt= hesis start pulling back but have not yet shown meaningful regression. This= window looks very similar to the tail end of an active protocol.

Weeks 2 to 4 post-discontinuation Fibr= oblast activation begins normalizing toward baseline. Active collagen synth= esis rates measurably decline during this window. However, the structural p= roteins already built continue to exist given their biological half-life. T= he gap between peak synthesis activity and current activity widens, but dep= osited collagen is not yet meaningfully degrading.

<= strong>Weeks 4 to 8 post-discontinuation This is the window = where research documents the most meaningful regression in active remodelin= g markers. The upstream signaling has largely normalized toward pre-protoco= l baseline by this point. Existing collagen continues its natural biologica= l turnover, but the replacement rate has dropped significantly without the = GHK-Cu stimulus driving synthesis. This is when the difference between peak= protocol activity and post-discontinuation state becomes most measurable.<= /span>

Beyond 8 weeks post-discontinuation= Without reintroduction of the signaling stimulus, collagen synthesis= rates settle at age-appropriate baseline levels. Previously deposited coll= agen continues normal biological turnover without being replaced at the ele= vated rate seen during the active protocol. Over months to a year or more, = the cumulative structural remodeling achieved during the protocol gradually= diminishes as natural degradation outpaces baseline synthesis.

<= p style=3D"margin: 0 0 20px 0;color: rgb(54,55,55);line-height: 26px;font-s= ize: 16px;">Sub-Q protocols show a similar post-discontinuation pattern, th= ough the larger baseline of structural remodeling achieved during the activ= e phase means the absolute level of collagen present remains higher for lon= ger compared to topical models.

Does everything retur= n to pre-protocol baseline?

Not immediately, and r= esearch suggests not fully in the short term. GHK-Cu’s influence on g= ene expression includes epigenetic markers that may persist beyond active a= dministration. Whether these changes are durable long term remains an activ= e area of research interest.

What the literature consistent= ly supports is that maintenance dosing sustains elevated collagen synthesis= activity more effectively than repeated cold-start protocols, given the cu= mulative nature of structural remodeling.

Bottom line=

GHK-Cu drives collagen synthesis through well-doc= umented signaling mechanisms. The structural proteins built during a protoc= ol have biological staying power well beyond discontinuation due to collage= n’s natural half-life. However, the cellular signal driving continued= production begins fading within the first few weeks of stopping, with the = most meaningful regression in active synthesis markers occurring in the 4 t= o 8 week post-discontinuation window. Peak activity will not be maintained = without continued administration, and maintenance dosing is better supporte= d in the literature than cycling repeatedly from baseline.

Upgrade to paid

You're currently a free subscriber to= Research Radar. For the f= ull experience, upgrade your subscription.

Upgrade to paid

 =
Share
&nb= sp;
 
<= td style=3D"vertical-align:middle;">
3D""Like
3D""Comment
=3D""Restack
 

© 2026 Derek Pruski
548 Market Street PMB 72296, San Francisco, CA 94104
Unsubscribe